Stanford just published research showing that blocking a single protein, 15-PGDH, doesn't just slow cartilage loss. It actually reverses it. In old mice, worn cartilage got thicker and functional again. After ACL-type injuries, the treatment prevented osteoarthritis from developing in roughly half the animals that would normally get it.
The mechanism is what gets me here. They weren't counting on stem cells to do the work. Instead, existing cartilage cells called chondrocytes shifted their gene activity back toward a younger state. The cells started producing healthy hyaline cartilage instead of the inferior fibrocartilage that shows up with degeneration.
Human tissue from knee replacement surgeries responded the same way. One week of exposure to the inhibitor and the samples began regenerating articular cartilage. Real cartilage. Not a workaround.
This matters because right now there's no drug that actually treats cartilage loss. We manage pain. Eventually, we replace the joint. The fact that they've got an oral 15-PGDH inhibitor already in human trials for muscle weakness means we're not starting from zero on safety. A cartilage trial could launch soon.
If this scales to patients the way it's performing in the lab, you're looking at a fundamentally different approach to aging joints. Not managing the decline. Reversing it.
https://www.sciencedaily.com/releases/2026/10/261005011249.htm